Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Center, Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Fremanezumab (675 mg Quarterly) in Female Patients Aged 18-45 With Menstrual Migraine

NCT06173661 is registered in ClinicalTrials.gov with Brigham and Women's Hospital as lead sponsor.

NCT NCT06173661
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06173661 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Center, Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Fremanezumab (675 mg Quarterly) in Female Patients Aged 18-45 With Menstrual Migraine
Lead sponsor
Brigham and Women's Hospital
Phase
Phase 4
Overall status
Completed
Start date
March 1, 2024
Completion date
July 13, 2026
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

menstrual migraine, menstrually related migraine, migraine